IL13RA2 and glioblastoma: Targeted therapies employing CAR-T cells, particularly those targeting B7-H3, EGFRvIII, and IL13Rα2, demonstrate promising results in preclinical and clinical settings, highlighting their potential as novel treatment modalities for recurrent glioblastoma.